PRIMARY INTRAVITREAL BEVACIZUMAB FOR SUBFOVEAL CHOROIDAL NEOVASCULARIZATION IN AGE-RELATED MACULAR DEGENERATION: Results of the Pan-American Collaborative Retina Study Group at 12 Months Follow-up

@article{Arvalo2008PRIMARYIB,
  title={PRIMARY INTRAVITREAL BEVACIZUMAB FOR SUBFOVEAL CHOROIDAL NEOVASCULARIZATION IN AGE-RELATED MACULAR DEGENERATION: Results of the Pan-American Collaborative Retina Study Group at 12 Months Follow-up},
  author={J. Ar{\'e}valo and J. Fromow-Guerra and JUAN G. Sanchez and M. Maia and Mar{\'i}a H. Berrocal and L. Wu and MARIO J. Saravia and ROGERIO A. Costa},
  journal={Retina},
  year={2008},
  volume={28},
  pages={1387-1394}
}
  • J. Arévalo, J. Fromow-Guerra, +5 authors ROGERIO A. Costa
  • Published 2008
  • Medicine
  • Retina
  • Purpose: To report the 12-month anatomic and Early Treatment Diabetic Retinopathy Study best-corrected visual acuity (BCVA) response after primary intravitreal bevacizumab (Avastin™, Genentech Inc., San Francisco, CA) (1.25 mg or 2.5 mg) in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration. Methods: Sixty-three eyes of 63 consecutive patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration, a mean age of… CONTINUE READING
    57 Citations

    References

    SHOWING 1-10 OF 42 REFERENCES
    Intravitreal bevacizumab for exudative age-related macular degeneration after multiple treatments
    • 41